Three large healthcare stocks—Pfizer, Medtronic, and Hinge Health—are leveraging AI to cut costs and improve patient outcomes across drug development, surgical robotics, and digital care platforms.
Pfizer's market value of US$152.5b reflects its scale in biopharmaceuticals with a deep late-stage pipeline; Medtronic (US$111.6b) deploys AI in operating rooms through robotic surgery; and Hinge Health (US$7.2b) focuses on AI-driven digital musculoskeletal care.
Each faces distinct risks—Pfizer has patent expiries and margin pressure, Medtronic is managing recalls and a complex spin-off, and Hinge Health trades at a high valuation while integrating acquisitions.
What happened
Three healthcare stocks—Pfizer (market value US$152.5b), Medtronic (US$111.6b), and Hinge Health (US$7.2b)—have been identified from a Transformative AI Healthcare screener as companies using AI to improve diagnostics, automation, and virtual care while managing constrained healthcare budgets.
Why it matters
Pfizer's late-stage pipeline in oncology, rare disease, and obesity could reshape earnings; Medtronic offers direct AI exposure through its Hugo robotic surgery system and Touch Surgery Aide platform; Hinge Health pairs growth in digital musculoskeletal care programs with expanding AI tools targeting margins above 35%. Together they show how AI is being deployed across pharma development, surgical automation, and digital care delivery.
What to watch
Pfizer faces patent expiries and dividend coverage risk despite a wide DCF discount; Medtronic must navigate product recalls and a complex Diabetes spin-off; Hinge Health trades at a high P/E and relies heavily on external funding while integrating the Cylinder Health acquisition into gastrointestinal care.
Ask the AI about this article →
The three stocks emerge from a broader Transformative AI Healthcare screener that identified 43 companies total, but these three exemplify distinct pathways for AI to reshape healthcare economics. Pfizer, as a US$62.3b Global Biopharmaceuticals Business with a smaller US$1.4b segment adjustment, operates at the intersection of large-scale pharma and AI-powered drug development; its late-stage pipeline in oncology, rare disease, and obesity positions it to reshape earnings mix over time, though recent margins have come under pressure and revenue is expected to decline for a few years even as earnings are forecast to grow. Medtronic, generating roughly US$36.4b in annual revenue across Cardiovascular (US$14.0b), Neuroscience (US$10.3b), and Medical Surgical (US$8.8b), brings AI directly into clinical workflows through surgical automation, but must contend with execution risk from product recalls and the complexity of a Diabetes spin-off. Hinge Health, smaller at US$7.2b market value with tightly-focused healthcare software revenue of US$720.1 million, represents a pure-play digital care model pairing AI motion tracking and wearables with expanding gastrointestinal care (via the Cylinder Health deal) and margin expansion targets. Across all three, the tension is consistent: transformative AI potential clashing with near-term financial headwinds and execution challenges.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
AI system scaling has pushed interconnect requirements inside data centers from chips and boards up to racks…
Chinese large-model developer Z.ai says it can now support large-scale inference using roughly 100,000 domesti…
Analyst Ming-Chi Kuo says Nvidia has revived the Rubin CPX AI accelerator with a substantially redesigned arch…
Palantir Technologies stock has posted multi-year gains, including an 11x return over 3 years
Apple has escalated its legal battle against OpenAI, claiming in a new court filing that OpenAI is actively de…
Samsung Electronics has locked up as much as 70% of its memory production capacity under long-term supply agre…
